124 related articles for article (PubMed ID: 12190310)
21. Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects.
Huang Y; Wei L; Han X; Chen H; Ren Y; Xu Y; Song R; Rao L; Su C; Peng C; Feng L; Wan J
Eur J Med Chem; 2019 Dec; 184():111749. PubMed ID: 31589992
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234
[TBL] [Abstract][Full Text] [Related]
23. Structural and biochemical characterization of fructose-1,6/sedoheptulose-1,7-bisphosphatase from the cyanobacterium Synechocystis strain 6803.
Feng L; Sun Y; Deng H; Li D; Wan J; Wang X; Wang W; Liao X; Ren Y; Hu X
FEBS J; 2014 Feb; 281(3):916-26. PubMed ID: 24286336
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
25. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
[TBL] [Abstract][Full Text] [Related]
26. Discovery of
Zhou J; Bie J; Wang X; Liu Q; Li R; Chen H; Hu J; Cao H; Ji W; Li Y; Liu S; Shen Z; Xu B
J Med Chem; 2020 Sep; 63(18):10307-10329. PubMed ID: 32820629
[TBL] [Abstract][Full Text] [Related]
27. Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase.
Lai C; Gum RJ; Daly M; Fry EH; Hutchins C; Abad-Zapatero C; von Geldern TW
Bioorg Med Chem Lett; 2006 Apr; 16(7):1807-10. PubMed ID: 16446092
[TBL] [Abstract][Full Text] [Related]
28. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase.
Shewchuk L; Hassell A; Wisely B; Rocque W; Holmes W; Veal J; Kuyper LF
J Med Chem; 2000 Jan; 43(1):133-8. PubMed ID: 10633045
[TBL] [Abstract][Full Text] [Related]
29. AMP inhibition of pig kidney fructose-1,6-bisphosphatase.
Kelley-Loughnane N; Kantrowitz ER
Biochim Biophys Acta; 2001 Jul; 1548(1):66-71. PubMed ID: 11451439
[TBL] [Abstract][Full Text] [Related]
30. A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase.
Heng S; Gryncel KR; Kantrowitz ER
Bioorg Med Chem; 2009 Jun; 17(11):3916-22. PubMed ID: 19419876
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
[TBL] [Abstract][Full Text] [Related]
32. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.
Cumming JG; McKenzie CL; Bowden SG; Campbell D; Masters DJ; Breed J; Jewsbury PJ
Bioorg Med Chem Lett; 2004 Nov; 14(21):5389-94. PubMed ID: 15454232
[TBL] [Abstract][Full Text] [Related]
33. [Recent advance in the discovery of allosteric inhibitors binding to the AMP site of fructose-1,6-bisphosphatase].
Li ZM; Bie JB; Song HR; Xu BL
Yao Xue Xue Bao; 2011 Nov; 46(11):1291-300. PubMed ID: 22260018
[TBL] [Abstract][Full Text] [Related]
34. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
[TBL] [Abstract][Full Text] [Related]
35. Structures of Leishmania Fructose-1,6-Bisphosphatase Reveal Species-Specific Differences in the Mechanism of Allosteric Inhibition.
Yuan M; Vásquez-Valdivieso MG; McNae IW; Michels PAM; Fothergill-Gilmore LA; Walkinshaw MD
J Mol Biol; 2017 Oct; 429(20):3075-3089. PubMed ID: 28882541
[TBL] [Abstract][Full Text] [Related]
36. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
Li RD; Zhang X; Li QY; Ge ZM; Li RT
Bioorg Med Chem Lett; 2011 Jun; 21(12):3637-40. PubMed ID: 21570843
[TBL] [Abstract][Full Text] [Related]
37. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
Hennequin LF; Thomas AP; Johnstone C; Stokes ES; Plé PA; Lohmann JJ; Ogilvie DJ; Dukes M; Wedge SR; Curwen JO; Kendrew J; Lambert-van der Brempt C
J Med Chem; 1999 Dec; 42(26):5369-89. PubMed ID: 10639280
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
39. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
Xu YY; Li SN; Yu GJ; Hu QH; Li HQ
Bioorg Med Chem; 2013 Oct; 21(19):6084-91. PubMed ID: 23962660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
